Clinuvel Pharmaceuticals Limited

CLINUVEL said revenue from sales increased 4% year over year to just under $37 million, with interest income up 14% to $5.3 million. Peter Vaughan said expenses rose 22% in the period, while net operating cash flow remained positive and cash reserves increased by $9 million to $233 million; net assets rose $8.2 million to just under $250 million. Management said profitability was lower but still maintained, and this was the 20th consecutive profit since commercial operations began. For the full financial year, Philippe Wolgen said the company expects to spend about $55 million to $58 million excluding capital expenditures. On the revenue mix, management said the current split is about 53% U.S. and 47% rest of world.

Philippe Wolgen framed the company as executing a deliberate, gradual strategy built on financial discipline and optionality. He said CLINUVEL intentionally increased spending on R&D, vitiligo, regulatory filings and internal capabilities, and that the model is intended to support a future diversified business rather than a short-term tradeoff. His tone was confident and methodical, emphasizing that cash reserves give the company flexibility to pursue vitiligo, NEURACTHEL, PhotoCosmetics and new manufacturing in-house.

Peter Vaughan highlighted consistent operating performance, noting revenue up 4% to just under $37 million, interest income of $5.3 million, and cash reserves up $9 million to $233 million. He said expenses were up 22%, including 16% higher personnel costs, 42% higher commercial distribution, 47% higher finance/corporate/legal costs tied partly to the ADR uplisting, and 191% higher other expenses from R&D programs. He also stressed that CLINUVEL remains debt-free for the 21st consecutive year, with no equity dilution since March 2016, and that the balance sheet supports funding the vitiligo program through commercialization.

Analysts focused on the vitiligo filing path, NEURACTHEL timing and geography, the impact of the FDA’s Bitopertin decision, Medicaid exposure, the NASDAQ uplisting, and the U.S./non-U.S. revenue mix. Management said vitiligo filing will wait for both CUV105 and CUV107, with EMA first and FDA second, while NEURACTHEL will be filed in Europe first via mutual recognition and then in the U.S. They said less than 5% of U.S. EPP patients are on Medicaid, so Medicaid cuts should not materially affect the business, and they attributed some U.S. sales pressure to the government shutdown delaying reimbursements. On Bitopertin, management argued CLINUVEL’s approved EPP position and SCENESSE’s safety record give it a stronger competitive position.